Clinical Trials Browser

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Phase 2/3 Recruiting

680 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

100 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Phase 2 Recruiting

49 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Not yet recruiting

46 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07455617 2026-04-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

Phase 1 Recruiting

101 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

29 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04512534 2026-04-02

Sincerely20

Phase 2 Recruiting

51 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07492342 2026-03-25

K-NADIR

Phase 2 Recruiting

30 enrolled

Thoracic

Resectable NSCLC

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2 Recruiting

276 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

344 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

430 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Phase 2 Recruiting

39 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

266 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

49 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

Phase 2 Recruiting

106 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Recruiting

280 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

Phase 2 Completed

10 enrolled 9 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Phase 3 Active not recruiting

446 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Phase NA Recruiting

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

Phase 2 Recruiting

37 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Phase 2 Active not recruiting

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07371611 2026-01-28

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Phase 3 Recruiting

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Phase 2 Recruiting

30 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms